Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1874-1879

  DiPaola, Robert S ^a   Rinehart, John ^a   Nemunaitis, John ^a   Ebbinghaus, Scott ^a   Rubin, Eric ^a   Capanna, Terry ^a   Ciardella, Marie ^a   Doyle Lindrud, Susan ^a   Goodwin, Susan ^a   Fontaine, Michelle ^a   Adams, Ned ^a   Williams, Adrienne ^a   Schwartz, Michael ^a   Winchell, Greg ^a   Wickersham, Karen ^a   Deutsch, Paul ^a   Yao, Siu Long ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; DOXORUBICIN DERIVATIVE; L 377202; LEUCINE DOXORUBICIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; OLIGOPEPTIDES; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036533873     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.001     Document Type: Article

References (12)

1. Clinical highlights from the National Cancer Data Base, 2000
2. Androgen-independent prostate cancer: Not so chemore fractory after all
3. A peptidedoxorubicin prodrug activated by prostate specific antigen selectively kills prostate tumor cells positive for prostate specific antigen in vivo
4. Prostate specific antigen expression by various tumors
5. The chymotrypsin like activity of human prostate specific antigen, gamma-seminoprotein
6. Enzymatic activity of PSA and its reactions with extracellular serine proteinase inhibitors
7. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse
8. Enzymatic activation of a doxorubicin-peptide prodrug by PSA
9. The chemotherapy of prostatic adenocarcinoma
10. Cardiotoxicity of doxorubicin and other anthracycline derivatives
11. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
12. Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study